Scientists at MIT and the Scripps Research Institute found that combining two substances to stimulate the immune system, ...

CVS Health will not cover Gilead's Yeztugo, generic name lenacapavir (LEN), citing "clinical, financial, and regulatory ...

A Russian HIV vaccine, based on mRNA technology, may be ready within the next two years, according to Vladimir Gushchin, the head of epidemiology at ...

The government has canceled nearly $500 million in research grants into the revolutionary technology, which experts believe ...

The owner of the U.S.' largest pharmacy benefit manager is declining to cover Gilead Sciences’ long-acting HIV prevention ...

The post New HIV Research Could Signal A Nanoparticle Breakthrough Cure For The Devastating Disease first on TwistedSifter. In 1959, the first case of HIV – the virus that causes AIDS – was confirmed ...

We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Gilead Sciences, Inc. is placed seventh among them. Gilead Sciences, Inc. (NASDAQ:GILD) is making headlines ...

EU clears lenacapavir (Yeytuo), the first twice-yearly HIV prevention injection, offering a major advance in HIV protection ...

Gilead Sciences’ twice-yearly injectable HIV-1 capsid inhibitor, Yeytuo receives European marketing authorization: Foster City, California Thursday, August 28, 2025, 12:00 Hrs [ ...

The European Commission has formally approved a twice-yearly injection to prevent HIV, clearing the way for the jab to be ...

The obesity epidemic will hit South Africa hard on top of our high HIV burden, but advocate researcher and scientist Dr ...